Abstinence
Case reports and uncontrolled observations can describe abstinence after exposure, but they cannot separate a drug effect from selection, setting, expectations, follow-up loss, or other care.
Ibogaine & alcohol use disorder
Research Overview
A careful primer on the human and translational research around ibogaine, noribogaine, and alcohol use disorder—what has been studied, what remains uncertain, and why safety context cannot be separated from any result.
This page summarizes a developing evidence base. It does not offer clinical recommendations or establish ibogaine as treatment for alcohol use disorder.
Evidence at a glance
Different questions have different levels of support
Alcohol use disorder is a clinical diagnosis with established treatments; the National Institute on Alcohol Abuse and Alcoholism’s overview of alcohol use disorder describes it as a condition assessed through patterns of impaired control and consequences, not by a single symptom. Ibogaine research does not yet provide comparable clinical certainty for AUD outcomes.
Craving
Changes in craving appear in early observational accounts and are plausible targets for research, yet standardized AUD-specific controlled data remain limited.
Withdrawal relief
Reports of symptom change do not establish a safe or effective withdrawal intervention. Alcohol withdrawal can be medically dangerous and requires appropriate assessment.
Relapse prevention
Long-term relapse prevention requires controlled follow-up, meaningful comparison groups, and careful accounting for concurrent treatment—features not yet robustly demonstrated here.
How to read the literature
Study types answer different questions
For alcohol use disorder specifically, the literature includes sparse case-level material, open-label and retrospective observations, and a larger translational field that includes animal work. The broader ibogaine research record should not be treated as interchangeable with evidence for AUD.
Case reports may surface hypotheses. Open-label series may show whether a protocol can be studied and what outcomes are worth measuring. Retrospective analyses can identify patterns and safety signals, but are especially vulnerable to incomplete records and confounding. Preclinical work can investigate mechanisms and guide future questions; it cannot establish a human clinical outcome.
That distinction matters when evaluating claims about whether ibogaine treatment works. A reported change after an intervention is not, by itself, evidence of causation or durable benefit.
Compound distinction
Ibogaine is not noribogaine
Ibogaine is metabolized into noribogaine, an active metabolite with a different pharmacologic profile and a longer persistence in the body. These are related compounds, but findings about one should not automatically be applied to the other.
Noribogaine has been investigated in early clinical development, including Phase 1 work, while that regulatory stage is not evidence of efficacy for alcohol use disorder. For context, the ClinicalTrials.gov trial registry is a useful primary record for checking a study’s stated design, status, and measured outcomes.
Accounts of ibogaine aftereffects should likewise be distinguished from controlled outcome data: duration, attribution, and severity need systematic measurement rather than anecdotal inference.
Methods note
What this digest includes—and does not infer
Selection approach
This overview considers human and translational studies available through 2026 that directly address ibogaine, noribogaine, alcohol-related outcomes, substance-use treatment contexts, pharmacology, or safety. It includes case reports, open-label series, retrospective analyses, clinical trial records, and relevant preclinical work.
It excludes promotional claims, unsupported outcome summaries, and accounts that do not identify a study design or a traceable source. A discussion of reported ibogaine therapy benefits should be read against those inclusion limits.
Interpretive limits
No pooled conclusion is offered here for abstinence, craving, withdrawal relief, or relapse prevention because the available AUD-specific evidence is not sufficiently consistent or controlled to support one. Terminology can also obscure evidence quality: the street names used for ibogaine do not identify a standardized medicine, protocol, or safety standard.
Questions about mood are separate from AUD outcomes. The evidence around ibogaine for depression and ibogaine and depression should not be used as indirect proof of alcohol-related benefit.
Gaps & safeguards
The unanswered questions are substantial
Ibogaine has documented safety concerns, including cardiac risk. The FDA’s drug development and approval process illustrates why staged evidence, monitoring, and review matter before treatment claims are established.
What would stronger AUD evidence require?
Prospectively designed studies with clear AUD criteria, defined dosing and monitoring, appropriate comparison groups, validated alcohol-use outcomes, adverse-event reporting, and follow-up sufficient to assess durability.
Why does setting matter?
Reported outcomes may reflect screening, medical oversight, preparation, other treatment, psychosocial support, and participant expectations. Cost and access also shape experiences; affordable ibogaine treatment discussions do not resolve questions of evidence quality or safety.
Are location-based claims evidence?
No. A place or provider label does not establish protocol quality, outcome validity, or regulatory status. This applies equally to searches for ibogaine treatment in Seattle.
Where does this fit in the wider site?
The broader evidence guide offers context for the topic, while the safety and risks material addresses the concerns that any interpretation of this research must keep in view.
A careful next step
Keep the difference between a research signal and a treatment claim clear.
For the principles guiding how this independent resource handles uncertainty, visit the organization’s evidence-first approach.